Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Invested Capital (2020 - 2025)

SAB Biotherapeutics' Invested Capital history spans 6 years, with the latest figure at $151.5 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 483.35% year-over-year to $151.5 million; the TTM value through Dec 2025 reached $151.5 million, up 483.35%, while the annual FY2025 figure was $151.5 million, 483.35% up from the prior year.
  • Invested Capital reached $151.5 million in Q4 2025 per SABSW's latest filing, down from $165.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $165.1 million in Q3 2025 to a low of $12.0 million in Q2 2025.
  • Average Invested Capital over 5 years is $46.8 million, with a median of $37.0 million recorded in 2022.
  • The largest YoY upside for Invested Capital was 483.35% in 2025 against a maximum downside of 73.95% in 2025.
  • A 5-year view of Invested Capital shows it stood at $42.5 million in 2021, then fell by 18.02% to $34.8 million in 2022, then skyrocketed by 64.56% to $57.3 million in 2023, then plummeted by 54.68% to $26.0 million in 2024, then skyrocketed by 483.35% to $151.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Invested Capital are $151.5 million (Q4 2025), $165.1 million (Q3 2025), and $12.0 million (Q2 2025).